CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Top winning strategies, by year, 2015-2017*
3.2.2.2. Top winning strategies, by development, 2015-2017* (%)
3.2.2.3. Top winning strategies, by company, 2015-2017*

3.3. Top player positioning, 2016
3.4. Porters five forces analysis
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. High investment for R&D activities pertaining to gene therapy
3.5.1.2. Increase in prevalence of cancer
3.5.1.3. Growth in awareness regarding gene therapy

3.5.2. Restraints

3.5.2.1. High cost associated with gene therapies
3.5.2.2. Unwanted immune responses

3.5.3. Opportunity

3.5.3.1. Untapped potential for emerging markets

CHAPTER 4: GENE THERAPY MARKET, BY VECTOR TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Viral vectors

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Market Analysis by country
4.2.5. Adenovirus
4.2.6. Lentivirus
4.2.7. Retrovirus
4.2.8. Adeno-associated virus
4.2.9. Herpes simplex virus
4.2.10. Poxvirus
4.2.11. Vaccinia virus
4.2.12. Others

4.3. Nonviral techniques

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Market Analysis by country
4.3.5. Naked plasmid vector
4.3.6. Gene gun
4.3.7. Electroporation
4.3.8. Lipofection
4.3.9. Others

CHAPTER 5: GENE THERAPY MARKET, BY GENE TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Antigen

5.2.1. Market size and forecast
5.2.2. Market size and forecast by country

5.3. Cytokine

5.3.1. Market size and forecast
5.3.2. Market Analysis, by country

5.4. Tumor suppressor

5.4.1. Market size and forecast
5.4.2. Market Analysis, by country

5.5. Suicide

5.5.1. Market size and forecast
5.5.2. Market Analysis, by country

5.6. Deficiency

5.6.1. Market size and forecast
5.6.2. Market Analysis, by country

5.7. Growth factors

5.7.1. Market size and forecast
5.7.2. Market Analysis, by country

5.8. Receptors

5.8.1. Market size and forecast
5.8.2. Market Analysis, by country

5.9. Others

5.9.1. Market size and forecast
5.9.2. Market Analysis, by country

CHAPTER 6: GENE THERAPY MARKET, BY APPLICATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Oncological disorders

6.2.1. Market size and forecast
6.2.2. Market Analysis, by country

6.3. Rare diseases

6.3.1. Market size and forecast
6.3.2. Market Analysis, by country

6.4. Cardiovascular diseases

6.4.1. Market size and forecast
6.4.2. Market Analysis, by country

6.5. Neurological disorders

6.5.1. Market size and forecast
6.5.2. Market Analysis, by country

6.6. Infectious diseases

6.6.1. Market size and forecast
6.6.2. Market Analysis, by country

6.7. Other diseases

6.7.1. Market size and forecast
6.7.2. Market Analysis, by country

CHAPTER 7: GENE THERAPY MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast, by country
7.2.4. Market size and forecast, by vector type
7.2.5. Market size and forecast, by gene type
7.2.6. Market size and forecast, by application

7.2.6.1. U.S. market size and forecast, by vector type
7.2.6.2. U.S. market size and forecast, by gene type
7.2.6.3. U.S. market size and forecast, by application
7.2.6.4. Canada market size and forecast, by vector type
7.2.6.5. Canada market size and forecast, by gene type
7.2.6.6. Canada market size and forecast, by application
7.2.6.7. Mexico market size and forecast, by vector type
7.2.6.8. Mexico market size and forecast, by gene type
7.2.6.9. Mexico market size and forecast, by application

7.3. Europe

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast, by country
7.3.4. Market size and forecast, by vector type
7.3.5. Market size and forecast, by gene type
7.3.6. Market size and forecast, by application

7.3.6.1. Germany market size and forecast, by vector type
7.3.6.2. Germany market size and forecast, by gene type
7.3.6.3. Germany market size and forecast, by application
7.3.6.4. France market size and forecast, by vector type
7.3.6.5. France market size and forecast, by gene type
7.3.6.6. France market size and forecast, by application
7.3.6.7. UK market size and forecast, by vector type
7.3.6.8. UK market size and forecast, by gene type
7.3.6.9. UK market size and forecast, by application
7.3.6.10. Italy market size and forecast, by vector type
7.3.6.11. Italy market size and forecast, by gene type
7.3.6.12. Italy market size and forecast, by application
7.3.6.13. Spain market size and forecast, by vector type
7.3.6.14. Spain market size and forecast, by gene type
7.3.6.15. Spain market size and forecast, by application
7.3.6.16. Rest of Europe market size and forecast, by vector type
7.3.6.17. Rest of Europe market size and forecast, by gene type
7.3.6.18. Rest of Europe market size and forecast, by application

7.4. Asia-Pacific

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast, by country
7.4.4. Market size and forecast, by vector type
7.4.5. Market size and forecast, by gene type
7.4.6. Market size and forecast, by application

7.4.6.1. Japan market size and forecast, by vector type
7.4.6.2. Japan market size and forecast, by gene type
7.4.6.3. Japan market size and forecast, by application
7.4.6.4. China market size and forecast, by vector type
7.4.6.5. China market size and forecast, by gene type
7.4.6.6. China market size and forecast, by application
7.4.6.7. India market size and forecast, by vector type
7.4.6.8. India market size and forecast, by gene type
7.4.6.9. India market size and forecast, by application
7.4.6.10. South Korea market size and forecast, by vector type
7.4.6.11. South Korea market size and forecast, by gene type
7.4.6.12. South Korea market size and forecast, by application
7.4.6.13. Rest of Asia-Pacific market size and forecast, by vector type
7.4.6.14. Rest of Asia-Pacific market size and forecast, by gene type
7.4.6.15. Rest of Asia-Pacific market size and forecast, by application

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast, by country
7.5.4. Market size and forecast, by vector type
7.5.5. Market size and forecast, by gene type
7.5.6. Market size and forecast, by application

7.5.6.1. Brazil market size and forecast, by vector type
7.5.6.2. Brazil market size and forecast, by gene type
7.5.6.3. Brazil market size and forecast, by application
7.5.6.4. South Africa market size and forecast, by vector type
7.5.6.5. South Africa market size and forecast, by gene type
7.5.6.6. South Africa market size and forecast, by application
7.5.6.7. Rest of LAMEA market size and forecast, by vector type
7.5.6.8. Rest of LAMEA market size and forecast, by gene type
7.5.6.9. Rest of LAMEA market size and forecast, by application

CHAPTER 8: COMPANY PROFILE

8.1. Adaptimmune Therapeutics Plc.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. Biocancell Ltd.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio

8.3. Bluebird Bio, Inc.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments

8.4. Celgene Corporation

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments

8.5. Gilead Sciences, Inc.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. Glaxosmithkline Plc

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. Merck & Co., Inc.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. Novartis AG

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. Oncogenex Pharmaceuticals, Inc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments

8.10. Spark Therapeutics, Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments